Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of INCB001158 with Epacadostat, with or without Pembrolizumab, in advanced solid tumors; trial terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Epacadostat (epacadostat)
• INCB001158
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Incyte Corporation | Conditions: Solid Tumors | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-05-21